Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 9/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6436290 | 0.90 | KMT2A (0.68) | MEN1KMT2AMAPTRAB9ATRPV1 | |
| SCHEMBL4345397 | 0.87 | TRPV1 (0.58) | DHODHMEN1KMT2AMAPTRAB9A | |
| SCHEMBL23831818 | 0.83 | DHODH (0.53) | DHODHMEN1KMT2AMAPTRAB9A | |
| SCHEMBL30105254 | 0.83 | DHODH (0.53) | DHODHMEN1KMT2AMAPTRAB9A | |
| SCHEMBL7105392 | 0.82 | MEN1 (0.76) | DHODHMEN1KMT2AMAPTRAB9A | |
| SCHEMBL22155057 | 0.79 | SMARCA2 (0.59) | MEN1KMT2AMAPTRAB9ALMNA | |
| SCHEMBL6227015 | 0.79 | MEN1 (0.71) | MEN1KMT2AMAPTRAB9ATRPV1 | |
| SCHEMBL6436281 | 0.79 | RAB9A (0.81) | MEN1KMT2AMAPTRAB9ANPSR1 | |
| SCHEMBL6435677 | 0.78 | MEN1 (0.58) | MEN1KMT2AMAPTRAB9ATRPV1 | |
| SCHEMBL23832105 | 0.77 | MEN1 (0.50) | DHODHMEN1KMT2AMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | DHODH 1210/4885MEN1 903/4885KMT2A 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.